Moderna price drops — what’s behind today’s move

Traders Union
All News
Financial News
Moderna Slides 5.12% Today to $25.30

Highlights

Ethic Inc. acquired 10,325 shares of Moderna on October 28, 2025, amid a reported 41.1% year-over-year revenue decline and consensus 2025 EPS forecast of -9.61.
AlphaQuest LLC increased its Moderna stake by over 400% on the same day, signaling significant institutional interest during ongoing earnings pressure.
Both institutional transactions coincided with Moderna's expansion efforts to grow its mRNA product pipeline beyond COVID-19 vaccines.

Investor accumulation rises despite revenue declines and profit warnings

Institutional activity increased as Ethic Inc. acquired 10,325 shares of Moderna on October 28, 2025, during a period of declining revenues, with the company's most recent quarterly result showing a 41.1% year-over-year drop and a consensus EPS forecast of -9.61 for 2025. On the same day, AlphaQuest LLC raised its stake in the company by over 400%, highlighting growing investor attention despite Moderna experiencing ongoing earnings pressure. Both transactions come as Moderna works to expand its mRNA product pipeline beyond COVID-19 vaccines.

Anton Kharitonov, expert at Traders Union, observes that while Moderna's fundamentals remain challenged by persistent revenue declines and negative EPS forecasts, recent institutional interest — such as Ethic Inc.'s purchase and AlphaQuest LLC’s significant stake increase — suggests lingering investor confidence amid a tough environment. He believes the negative sentiment reflected in earnings pressure is partially offset by news of pipeline expansion, yet buyers are cautious. "Although institutional buying hints at renewed curiosity, the majority of participants are likely waiting for firmer signs of stabilization before making meaningful commitments."

Viktoras Karapetjanc, expert at Traders Union, sees Moderna’s trajectory as heavily shaped by macro headwinds, particularly sector-wide shifts away from COVID-19 priorities and heightened earnings volatility. He believes global investor flows and the shift in healthcare spending patterns amplify both risk and opportunity, especially as institutional portfolio adjustments emerge. "In the short term I expect macroeconomic pressures to keep weighing on the stock, with broader risk appetite needed to spark any sustainable recovery."

Jainam Mehta, market strategist, takes a critical stance, noting that Moderna’s current breakdown below major moving averages, combined with persistent negative momentum and weak technical signals, presents a worrying picture. He underscores that oversold conditions are failing to attract buyers, which reinforces the vulnerability of the stock. "At these levels, I remain skeptical of any near-term rebound, as sellers clearly have the upper hand for now."

Mixed momentum signals underline oversold status and bearish pressure

Momentum signals are mixed on the daily chart. The MACD shows strong buy, but ADX is weak and points to a sell, indicating unclear trend strength. RSI at 46.1 and D1 Stochastic RSI at an oversold 9.3, supported by CCI around neutral and subzero, suggest the stock is approaching oversold but without strong bullish reversal evidence. The current price is down $1.37, slipping 5.12% today. There was no significant gap between the previous close and today’s open. The stock is currently near the daily low of the $25.26 — $26.87 range, showing high intraday volatility and sustained downside pressure after the opening. Sellers maintain dominance per BBP, and the Awesome Oscillator confirms the prevailing bearish direction. Momentum and oscillator signals are diverging, with oversold readings not yet attracting buyers as price action and momentum remain negative.

Previously it was noted that bullish momentum runs into resistance as the stock faces mixed technical signals. Additionally, positive vaccine trial results and ongoing advances in the development of new mRNA therapies were highlighted as supporting factors for the company's strategic pipeline.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.